Wave expects to initiate a Phase 2a multidose portion of WVE-007 INLIGHT clinical trial in individuals living with obesity ...
Initial AX-0810 data show no safety signals after 4 weeks of dosing and pharmacokinetics consistent with non-clinical data; ...
New research led by Joshua Rosenthal, PhD, of the Marine Biological Laboratory (MBL) and Eli Eisenberg, PhD, at Tel Aviv University, has revealed that octopuses and their close relatives adjust to ...
Adenosine deaminase acting on RNA (ADAR) is the enzyme responsible for adenosine-to-inosine (A-to-I) RNA editing, a process ...
Maddy has a degree in biochemistry from the University of York and specializes in reporting on health, medicine, and genetics. Maddy has a degree in biochemistry from the University of York and ...
Ascidian Therapeutics ("Ascidian"), a biotechnology company seeking to treat human diseases by rewriting RNA, and Forge ...
In a paper published on aBIOTECH, the authors investigated the off-target effects of ADAR-mediated RNA editing in rice ...
The most recent developments in the field of A-to-I RNA modification, with a special emphasis on the roles of A-to-I in the genesis and progression of cancer. Adenosine-to-inosine (A-to-I) RNA editing ...
ProQR Therapeutics is advancing its Axiomer ADAR-mediated RNA editing pipeline, aiming to file a Clinical Trial Application for its lead program AX-0810, targeting NTCP for cholestatic diseases, by Q2 ...
New research provides a mechanistic map of how genetic mutations disrupt RNA splicing in acute myeloid leukemia.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback